Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/593,468	IKEDA ET AL.	
Exami <i>n</i> er	Art Unit	
		I
FRANK D. DUCHENEAUX	1787	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 08 April 2010 FAILS TO PLACE THIS APPLICATION	N IN CONDITION FOR ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or on the same application, applicant must timely file one of the following replies: (1 application in condition for allowance; (2) a Notice of Appeal (with a for Continued Examination (RCE) in compliance with 37 CFR 1.114 periods:	I) an amendment, affidavit, or other evidence, which places the appeal fee) in compliance with 37 CFR 41.31; or (3) a Request
a) The period for reply expires 5 months from the mailing date of the final	I rejection.
b) The period for reply expires on: (1) the mailing date of this Advisory Ac no event, however, will the statutory period for reply expire later than S	tion, or (2) the date set forth in the final rejection, whichever is later. In
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).	
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the have been filled is the date for purposes of determining the period of extension and under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened set forth in (b) above, if checked. Any reply received by the Office later than three may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	d the corresponding amount of the fee. The appropriate extension fee statutory period for reply originally set in the final Office action; or (2) as
The Notice of Appeal was filed on A brief in compliance wit filing the Notice of Appeal (37 CFR 41.37(a)), or any extension ther Notice of Appeal has been filed, any reply must be filed within the ti	reof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a
<u>AMENDMENTS</u>	
 The proposed amendment(s) filed after a final rejection, but prior to (a) They raise new issues that would require further consideration (b) They raise the issue of new matter (see NOTE below); 	
(c) ☐ They are not deemed to place the application in better form for appeal; and/or	or appeal by materially reducing or simplifying the issues for
(d) ☐ They present additional claims without canceling a correspon	ding number of finally rejected claims.
NOTE: see Attachment to Advisory Action. (See 37 CFR 1.	116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See at	ttached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):	
 Newly proposed or amended claim(s) would be allowable if non-allowable claim(s). 	submitted in a separate, timely filed amendment canceling the
7. For purposes of appeal, the proposed amendment(s): a) will no how the new or amended claims would be rejected is provided belo The status of the claim(s) is (or will be) as follows:	
Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>1,3 and 5-7</u> . Claim(s) withdrawn from consideration:	
AFFIDAVIT OR OTHER EVIDENCE	
 The affidavit or other evidence filed after a final action, but before o because applicant failed to provide a showing of good and sufficien was not earlier presented. See 37 CFR 1.116(e). 	
9. The affidavit or other evidence filed after the date of filing a Notice of entered because the affidavit or other evidence failed to overcome showing a good and sufficient reasons why it is necessary and was	all rejections under appeal and/or appellant fails to provide a
10. The affidavit or other evidence is entered. An explanation of the st REQUEST FOR RECONSIDERATION/OTHER	tatus of the claims after entry is below or attached.
11. \square The request for reconsideration has been considered but does NC	OT place the application in condition for allowance because:
12. Note the attached Information <i>Disclosure Statement(s)</i> . (PTO/SB/113. Other:	08) Paper No(s)
0 : D : . E : A : !! : . 4707	FRANK D DUCHENEAUX/ ixaminer, Art Unit 1787